{"nctId":"NCT02600325","briefTitle":"Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV","startDateStruct":{"date":"2016-02","type":"ACTUAL"},"conditions":["Acute Hepatitis C","Human Immunodeficiency Virus","Hepatitis C"],"count":80,"armGroups":[{"label":"Treatment group","type":"EXPERIMENTAL","interventionNames":["Drug: Grazoprevir/Elbasvir 100mg/50mg"]}],"interventions":[{"name":"Grazoprevir/Elbasvir 100mg/50mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. HIV positive\n2. Acute HCV genotype 1 or 4 infection (≤26 weeks old at the baseline visit)\n\nExclusion Criteria:\n\n1. Not on cART and a CD4 \\<500 at the time of screening\n2. Patients on cART for \\>6 months with a HIV viral load \\>400 copies\n3. Disallowed co-medication that cannot be stopped or replaced\n4. History of liver cirrhosis of any etiology. Inclusion of patients with a chronic well-controlled HBV (HBV-DNA \\<below the limit of detection) is allowed if fibroscan excludes \\>F1 fibrosis\n5. Protease inhibitor based and NNRTI based cART regimens are not allowed. Therefore, the inability to switch to a HAART regimen consisting of 2 nucleoside/tide reverse transcriptase inhibitors and an allowed third agent which can be raltegravir (Isentress®) 400mg BID, dolutegravir (Tivicay) 50mg QD or rilpivirine 25mg QD.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"SVR12 (Reinfection Not Considered Failure)","description":"Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are not considered failure","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"SVR12 (Reinfection Equals Failure)","description":"Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are considered failure","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":80},"commonTop":["Fatique","headache","insomnia","mood changes","dyspepsia"]}}}